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Abstract. Oligoribonucleotides conjugates and the corresponding siRNA duplexes 
against tumor necrosis factor carrying one, two or four glucose and galactose residues at 
the 5’-end have been prepared using phosphoramidite chemistry. Carbohydrate-
modified siRNA duplexes displayed similar or slightly reduced inhibitory properties 
compared to unmodified RNA duplexes in HeLa cells upon transfection with 
oligofectamine. When HeLa cells were treated with siRNA carrying one, two or four 
glucose residues without oligofectamine, no inhibition was observed. The inhibitory 
properties of siRNA carrying galactose residues without transfecting agent were tested 
on HuH-7 cells that have abundant asialoglycoprotein receptors. In these cells siRNA 
carrying galactose residues have slight anti-TNF inhibitory properties (25% in the best 
case) that are eliminated if the receptors are blocked with a competitor such as a-D-
galactopyranosyl-albumine. These results demonstrate receptor-mediated uptake of 
siRNA carrying galactose residues although the efficacy of the process is not enough for 
efficient RNA interference experiments.    
 
INTRODUCTION 
Chemically synthesized DNAs and RNAs have shown promising results as potential 
drugs [1, 2]. In these cases nucleic acids are used for the inhibition of a specific gene by 
blocking gene translation or gene transcription or by stimulating the degradation of a 
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particular messenger RNA. In the antisense strategy synthetic oligonucleotides 
complementary to the messenger RNA of a given gene are used to inhibit translation of 
mRNA to protein [1,3,4]. On the other hand, small interfering RNA duplexes  (siRNA) 
are used to inhibit a specific gene expression by the RNA interference (RNAi) 
mechanism. This is a cellular post-transcriptional gene silencing mechanism induced by 
a double stranded siRNA. In this strategy one of these strands binds to a protein called 
RISC and the complex formed is able to cleave the complementary mRNA sequence so 
that the corresponding protein is not formed [5-7]. Although large efforts have been 
devoted in the development of novel siRNA derivatives for gene silencing, the clinical 
potential of siRNA is still limited mainly due low stability and inefficient delivery of 
siRNAs.  
Chemical modification of DNA or RNA strands has been addressed as one promising 
strategy to solve these inconvenients [8-10]. Conjugation with different molecules such 
as lipids, peptides, aptamers or polymers has been used to improve pharmacokinetic 
properties of siRNA without decreasing activity [9]. Synthesis of carbohydrate 
conjugates is a potential alternative to enhance oligonucleotide uptake by using sugar 
binding membrane receptors to mediate cell entry [10,11]. Oligonucleotide delivery in 
the form of covalent conjugates with carbohydrates is not as well explored as in the 
form of non covalent complexes [10]. Because the interaction between individual 
carbohydrates and lectins is rather weak, multivalent carbohydrate moieties linked to 
oligonucleotides may enhace the affinity.  In the antisense strategy, galactosylated PEG-
conjugates of oligonucleotides phosphorothioates have been shown to enhance uptake 
by galactose-specific asialoglycoprotein receptor-mediated endocytosis [12]. 
Multivalent carbohydrate conjugates have been described in order to increase the 
interaction of carbohydrates with cellular receptors [13-16]. Oishi et al described the 
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synthesis of siRNA conjugates with lactose and polyethyleneglycol at the 3’-end of the 
passenger strand. This modification improved gene inhibition in hepatoma cells [17]. 
Glycotargeting is considered a valuable method to enhance delivery of therapeutic 
oligonucleotides. Moreover, selectivity between different cell types can be achieved if 
different carbohydrate binding receptors are expressed. This is the case with a 
membrane-active polymer with N-acetyl galactosamine covalently attached, which  
preferentially accumulated the oligonucleotides in hepatocyte cells whereas if mannose 
was attached to the polymer the dsDNA went preferentially to nonparenchymal and 
Kupffer cells, which possess mannose receptors, and away from hepatocytes [18]. 
Synthesis of oligonucleotide conjugates with carbohydrates has been reviewed [19,20]. 
There are three main protocols reported for the solid phase synthesis of 
glycoconjugates. Carbohydrate phosphoramidite coupling is the oldest and one of the 
most used so far [13-15, 21-23]. Synthesis of oligonucleotide glycoconjugates can also 
be performed using a 1,3-dipolar cycloaddition (“click reaction”) of sugar azides and 
support-anchored alkynylated oligonucleotides [24]. Moreover, sugar oligonucleotide 
conjugates have also been prepared by solid phase oximation with carbohydrate mono-
substitution [25] or displaying sugar multivalency [26]. Few examples for carbohydrate-
RNA conjugates have been described. In these cases sugar attachment has been carried 
out using an amide bond [27], an oxime bond [28], a 3,4-diethoxy-3-cyclobutene-1,2-
dione as linker [29], or a long functional spacer built with an amide bond (containing 
sugar and spacer) and a Michael reaction between the sugar acrylate derivative and a 5’-
thiol-modified RNA [17]. 
In this paper we describe, for the first time, the synthesis of carbohydrate conjugates of 
oligoribonucleotides (1-6) using phosphoramidite chemistry (scheme 1). These 
modifications are introduced to the passenger strand of the siRNA for the inhibition of 
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tumor necrosis factor (TNF-α) protein which is involved in apoptosis, inflammation and 
immunity processes [30]. We envisioned that the introduction of multiple carbohydrates 
(glucose or galactose) at the 5’-terminus of  the passenger strand may favour cellular 
uptake by receptor-mediated endocitosis as the number of carbohydrate residues is 
increased.  
  
EXPERIMENTAL SECTION 
 
Oligonucleotides.  
The following RNA sequences were obtained from commercial sources (Sigma-Proligo, 
Dharmacon): sense or passenger scrambled 5’-CAGUCGCGUUUGCGACUGG-dT-
dT-3’, antisense or guide scrambled 5’-CCAGUCGCAAACGCGACUG-dT-dT-3’, 
antisense or guide anti-TNFa: 5’-GAGGCUGAGACAUAGGCAC-dT-dT-3’ and sense 
or passenger anti-TNFa: 5’-GUGCCUAUGUCUCAGCCUC-dT-dT-3’. RNA 
monomers in capital letters, dT represents thymidine. The anti-TNFa siRNA has been 
previously described to efficiently downregulate murine TNFa mRNA [30]. 
 
3-Hydroxypropyl-2,3,4,6-tetra-O-acetyl-b-D-glucopyranoside (7). To a solution 
of the tetra-O-acetylglucopyranosyl bromide [31]  (730 mg, 1.78 mmol) in anhydrous 
CH2Cl2 (40 mL) was added Na2SO4 (two lips of spatula) and 1,3-propanediol (1.43 mL, 
17.8 mmol). Alter stirring at room temperature for 15 min, under argon atmosphere, 
Ag2CO3 (4.9 g, 17.8 mmol) was added to the reaction mixture and was stirred for 96 
hours (TLC hexane-ethyl acetate, 2:3). The mixture was then filtered over celite and the 
crude was purified by silica gel column chromathography using as eluent (hexane-ethyl 
acetate, 2:3) to give 7 (390 mg, 54%) as a syrup. [α]D20 -12.3 (c 1 in CHCl3); 1H-NMR 
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(CDCl3, 300 MHz) δ (ppm) 5.15 (t, J = 9.5 Hz, 1H, ), 5.01 (t, J= 9.6 Hz, 1H), 4.91 (m, 
1H, ), 4.47 (d, J= 7.9 Hz, 1H, H1), 4.18 (dd, J= 12.3 & 4.7 Hz, 1H, H6), 4.09 (dd, J= 
12.3 & 2.3 Hz, 1H, H6), 3.93 (td, J= 9.6 & 5.9 Hz, 1H), 3.63 (m, 4H, 2 x CH2O-), 2.18 
(s, 1H, OH), 2.03, 1.98, 1.96, 1.94 (4s, 12H, 4 x OCOCH3), 1.75 (dd, J= 5.7 & 4.7 Hz, 
2H, -OCH2CH2CH2O-). 13C-NMR (CDCl3, 75 MHz) δ (ppm) 171.1 (C=O), 170.6 
(C=O), 169.9 (C=O), 169.8 (C=O), 101.1 (C1), 73.1, 72.2, 71.6, 68.8, 68.0, 62.3, 60.2, 
32.5 (CH2CH2CH2), 21.1 (OCOCH3), 21.0 (OCOCH3), 20.9 (OCOCH3), 20.9  
(OCOCH3). HRMS (ES+) Calcd. for C17H26O11 (M+H): 407.1553, found; 407.1555.  
 
3-[(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyloxy)]propyl (2-cyanoethyl) (N,N-
diisopropyl) phosphoramidite (8). Diisopropylethylamine (DIEA) (0.040 mL, 0.228 
mmol) and 2-cyanoethyl-N,N’-diisopropylamino-chlorophosphoramidite (20 mL, 0.092 
mmoL) were added to a solution of compound 7 (25.0 mg, 0.061 mmol) in anhydrous 
CH2Cl2 (2 mL) at room temperature under an argon atmosphere. After 1.0 h no starting 
material was observed. Solvent was then removed and the crude was purified by silica 
gel column chromatography by using hexane-ethyl acetate (1:1 with 5% of 
triethylamine) to give compound 8 (35 mg, 95%) as a syrup. 1H-NMR (CDCl3, 300 
MHz) (mix of isomers) δ (ppm) 5.13 (dt, J =4.2 & 9.5 Hz, 1H, H3), 5.01 (t, J= 9.6 Hz, 
1H, H4), 4.90 (t, J= 8.6 Hz, 1H, H2), 4.45 (t, J= 8.3 Hz, 1H, H1), 4.20 (dd, J= 12.1 & 
4.0 Hz, 1H, H6), 4.05 (d, J= 12.1 Hz, 1H, H6’), 3.93-3.84 (m, 1H, H5), 3.83-3.44 (m, 
8H, 2 x CH2O- + -OCH2CH2CN + 2CHisopropyl), 2.63-2.53 (m, 2H, -OCH2CH2CN), 2.01, 
1.98, 1.95, 1.93 (4s, 12H, 4 x OCOCH3), 1.80 (m, 2H, -OCH2CH2CH2O-), 1.11 (d, 12H, 
J=6.5 Hz, 4CH3isopropyl). HRMS (ES+) Calcd. for C26H44N2O12P (M+H): 607.2632, 
found; 607.2638. 
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Synthesis of oligoribonucleotide-carbohydrate conjugates. 
Oligoribonucleotide carrying carbohydrates at the 5’-end were synthesized by a DNA 
synthesizer (Applied Biosystems 3400) using 2-cyanoethyl phosphoramidites and 
polystyrene solid supports (LV200). The following sequences were prepared: Glucose-
C3-5'-GUG CCU AUG UCU CAG CCU C-dT-dT-3’, (Glucose-C2)2-DB-GUG CCU 
AUG UCU CAG CCU C-dT-dT-3’, (Glucose-C2)4-DB-DB-GUG CCU AUG UCU 
CAG CCU C-dT-dT-3’, Galactose-C2-5'-GUG CCU AUG UCU CAG CCU C-dT-dT-
3’, (Galactose-C2)2-DB-GUG CCU AUG UCU CAG CCU C-dT-dT-3’, (Galactose-
C2)4-DB-DB-GUG CCU AUG UCU CAG CCU C-dT-dT-3’. DB stands for the 
symmetric doubler phosphoramidite obtained from commercial sources (Glen 
Research); C3 stands for -CH2CH2CH2-OPO2--; C2 for -CH2CH2-OPO2--; and dT for 
thymidine. The synthesis of carbohydrate phosphoramidites of Glucose-C2 (9) and 
Galactose-C2 (10) is described in [14, 15] whereas details for the preparation of 
Glucose-C3 phosphoramidite (8) are described above. Guanosine was protected with the 
dimethylaminomethylidene group, cytidine was protected with the acetyl group and 
adenosine with the benzoyl group. The 2’-OH protecting group for the RNA monomers 
was the t-butyldimethylsilyl (TBDMS) group. The phosphoramidites were dissolved in 
dry acetonitrile (0.1M) and a modified cycle was used with increased coupling time (10 
min). The solid supports were treated with concentrated aqueous ammonia-ethanol (3:1) 
for 1hr at 55oC. After filtration of the solid supports,  the supports were washed with 
ethanol and the combined solutions were evaporated to dryness.  Sequences were 
treated with 0.15 ml of triethylamine hydrofluoride / triethylamine / N-
methylpyrrolidone (4:3:6) for 2.5 hours at 65 ºC to remove the t-butyldimethylsilyl 
groups. The reactions were stopped by addition of 0.3 ml of isopropoxytrimethylsilane 
and 0.75 ml of ether. The resulting mixtures were mixed with the vortex and cooled at 4 
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ºC. A precipitate was formed that was centrifugated at 7000 rpm, 5 min at 4ºC. The 
precipitates were washed with ether and centrifuged again. The residues were dissolved 
in water and the conjugates were purified by HPLC. HPLC conditions were:  column: 
Nucleosil 120-10 C18 (250x4 mm); 20 min linear gradient from 0%  to 50% B (DMT off 
conditions); flow rate 3 ml/min; solution A was 5% acetonitrile in 0.1 M aqueous 
triethylammonium acetate (TEAA) buffer and B 70% acetonitrile in 0.1 M aqueous 
TEAA. The purified products were analyzed by MALDI-TOF mass spectrometry. 
MALDI-TOF spectra were performed using a Perseptive Voyager DETMRP mass 
spectrometer, equipped with nitrogen laser at 337 nm using a 3ns pulse. The matrix 
used contained 2,4,6-trihydroxyacetophenone (THAP, 10 mg/ml in ACN/ water 1:1) 
and ammonium citrate (50 mg/ ml in water). Glucose-C3-RNA 1 [M] = 6861 (expected 
M= 6858). (Glucose-C2)2-DB-RNA 3 [M] = 7476 (expected M= 7478). (Glucose-C2)4-
DB-DB-RNA 5 [M] = 8755 (expected M= 8754). Galactose-C2-RNA 2 [M] = 6847 
(expected M= 6841). (Galactose-C2)2-DB-RNA 4 [M] = 7461 (expected M= 7478). 
(Galactose-C2)4-DB-DB-RNA 6 [M] = 8746 (expected M= 8754). Yields (0.2 mmol 
scale synthesis) were between 15-20 OD units at 260 nm. Melting temperatures of 
siRNA duplexes (15 mM HEPES-KOH pH 7.4; 1 mM MgCl2, 50 mM potassium 
acetate) : Unmodified 83.3 ºC; 1 83.7 ºC; 2 84.7 ºC; 5 82.1 ºC; 6 83.0 ºC. 
 
Cell culture, transfection and cellular assays.  
HeLa cells were cultured under standard conditions (37ºC, 5% CO2, Dulbecco’s 
Modified Eagle Medium, 10% fetal bovine serum, 2mM L-glutamine, supplemented 
with penicillin (100 U/ml) and streptomycin (100mg/ml).  All in vitro experiments were 
conducted at 40-60% confluence. HeLa cells were transfected with 250 ng of murine 
expressing TNF-a plasmid using lipofectin (Invitrogen) according to the manufacturer’s 
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instructions. One hour following transfection murine TNF-a expressing HeLa cells 
were transfected with 50nM of siRNA (5’-GUGCCUAUGUCUCAGCCUC-dT-dT-3’ / 
5’ GAGGCUGAGACAUAGGCAC-dT-dT-3’, [30]) against TNF-a, using 
oligofectamine (Invitrogen). TNF-a concentration was determined from cell culture 
supernatant by enzyme-linked immunoabsorbent assay kit (Bender MedSystems) 
according to the manufacturer’s instructions.  
 
RESULTS AND DISCUSSION 
 
Synthesis of oligoribonucleotide carrying glucose and galactose  
Among the different approaches described to prepare carbohydrate oligonucleotide 
conjugates [19,20] we selected the protocol based on the coupling of a sugar 
phophoramidite to oligonucleotides on a solid support. This approach has been 
previously used in our group to introduce several sugars in DNA [14,15]. We have 
extended this approach to prepare RNA-carbohydrate conjugates that possess one, two 
and four glucose or galactose moieties. Glucose and galactose phosphoramidites  
carrying C2 and C3 spacers (scheme 2) were synthesized in two steps: classical 
glycosylation from their corresponding bromo peracetylated sugars and ethylene glycol 
or propylene glycol and subsequent standard phosphoramidite chemistry as described in 
[14,15].  
Oligoribonucleotide carrying glucose and galactose at the 5’-end were synthesized. 
using the appropriate carbohydrate phosphoramidites (Scheme 2) and the commercial 
dendrimer symmetric doubler phosphoramidite. We selected the 21mer RNA sequence 
5'-GUGCCUAUGUCUCAGCCUC-dT-dT-3’ for the introduction of one or several 
 10
glucose or galactose moieties at the 5’-end . This RNA sequence is the passenger strand 
of a siRNA described to downregulate TNF-a [30].  Oligonucleotides presented a major 
peak with some impurities (Figure 1) that were easily separated by HPLC obtaining the 
desired conjugates in good yields after HPLC purification. As described in [14] some 
side products were observed after the synthesis of the branched oligonucleotides that 
lack one or two glucose or galactose residues. It is described that phosphoramidite 
couplings after branching are somehow less efficient [32] but this fact did not prevent 
obtaining pure RNA conjugates with two and four glucose or galactose units. Mass 
spectrometry analysis confirmed the expected molecular weight. Denaturation melting 
curves of siRNA duplexes formed by mixing unmodified guide strand and passenger 
RNA strands 1, 2, 5 and 6 shown little diferences (experimental section) compared with 
unmodified siRNA. These results indicate that the presence of carbohydates at the 5’-
end of the passenger strand do not affect hybridization properties of modified RNA 
strands.  
Inhibition of TNF-a. 
Tumor necrosis factor (TNF-a) was selected as a target for RNA interference studies. 
This protein is a major mediator of apoptosis as well as inflammation and immunity, 
and it has been implicated in the pathogenesis of a wide spectrum of human diseases. 
Therefore, the inhibition of TNF-a is of special interest especially for the development 
of antiflammatory drugs. Oligoribonucleotide sequences carrying carbohydrates at the 
5’-end of the passenger strand were annealed with equimolar amounts of the unmodified 
guide strand and the resulting duplexes were used for inhibition of the expression of the 
TNF-a gene. HeLa cells were transfected first with the murine TNF-a plasmid using 
lipofectin and one hour later were co-transfected with the siRNA duplex (50 nM) using 
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oligofectamine. After 24 hrs the amount of TNF-a produced by the cells was analyzed 
by enzyme-linked immunoabsorbent assay (ELISA). Figures 2 and 3 show the amount 
of TNF-a produced after 24 hrs of transfection of 50nM siRNA unmodified duplex 
(Unmodified), 50 nM of the same siRNA duplex carrying one, two or four glucose 
(Figure 2) or galactose (Figure 3) residues at the 5’-end of the passenger strand and 50 
nM of a scrambled RNA duplex control sequence (Scr). Both, single modified and 
unmodified siRNA against TNF-a produced an 80-90% inhibition of the production of 
TNF-a compared with the scrambled control siRNA duplex.  However, the presence of 
either two or four carbohydrate residues produced a decrease of the inhibitory 
properties. These results indicate that the introduction of either glucose or galactose at 
the 5’-end of the passenger strand of an RNA duplex is well tolerated by the RNAi 
machinery in HeLa cells although branching somehow reduces the inhibitory properties 
of the resulting siRNA duplex about 2-fold.  
In addition we have analyzed the inhibition of the TNF-a production in Hela cells by 
the siRNA duplexes carrying glucose without using oligofectamine (Figure 4). In this 
case no inhibition of the TNF-a production was noted indicating that the siRNA 
duplexes carrying one, two or four glucose residues are unable to enter HeLa cells.  
In order to evaluate the potential uptake of siRNAs carrying galactose, human hepatoma 
HuH-7 cells were used. These cells have abundant asialoglycoprotein receptors as 
shown by incubation of a-D-galactopyranosyl-albumine labelled with 
tetramethylrhodamine phenylisotiocyanate (a-D-galactopyranosyl-TRITC-albumine, 
Sigma) (supplementary data). HuH-7 cells were transfected with the murine TNF-a 
plasmid using lipofectin and one hour later were treated with the corresponding siRNA 
duplexes (100 nM) without transfecting agent. After 48 hrs the amount of TNF-a 
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produced by the cells was analyzed by ELISA (Figure 5). A small inhibition of TNF-a 
(up to 25%) was observed with the siRNAs carrying galactose with no significant 
differences between the siRNAs having 1, 2 or 4 galactoses.  It has been described that 
transfection of galactose derivatives may be inhibited by galactosylated proteins such as 
asialofetuin [33]. In order to confirm that the small inhibitory properties of siRNAs 
carrying galactoses were due to asialoglycoprotein receptor mediated uptake we 
analysed the amount of TNF-a produced by the HuH-7 cells in the presence of a large 
excess of a-D-galactopyranosyl-TRITC-albumine that is a ligand for asialoglycoprotein 
receptor. Figure 6 shows that in the presence of the competitor no inhibition of TNF-a 
is observed. These results indicate that, most probably, the inhibition of TNF-a by 
siRNA carrying galactose is mediated by asialoglycoprotein receptor uptake. 
Unfortunately the efficacy of the uptake is low for the practical use of these siRNA 
conjugates without transfecting agent. Ideally the carbohydrate moiety should be 
separated from the oligonucleotide to optimize binding efficiency [34, 35]. However, 
results from antisense studies using oligonucleotide conjugates with carbohydrates 
similar to our work showed good results in antisense inhibition of gene expression [36].    
In conclusion we have studied the effect of the 5’-insertion of one, two or four glucose 
or galactose units on the inhibitory properties of siRNA duplexes. siRNA duplexes 
covalently linked to carbohydrates can be efficiently delivered to HeLa cells and these 
conjugates enter the RNAi pathway to silence gene expression with similar or slightly 
reduced efficiency compared to unmodified siRNA duplexes. When HeLa cells were 
treated with siRNA carrying glucose residues without oligofectamine, no inhibition was 
observed. On the contrary, some inhibition of the expression of TNF-a was found when 
galactose modified siRNAs are used without transfection agent in HuH-7 cells that have 
abundant asialoglicoprotein receptors. This inhibition was eliminated when the 
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receptors are blocked with a competitor. These results indicate a possible mediation of 
cellular asialoglicoprotein receptors in the uptake of galactose-siRNA conjugates.  
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Scheme 1. Structure of the carbohydrate oligodeoxyribonucleotide conjugates prepared. 
RNA seq is passenger anti-TNF-a sequence: 5’-GUGCCUAUGUCUCAGCCUC-dT-
dT-3’. 
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Scheme 2. Sugar phosphoramidites (8-10) used in this work for the preparation of 
oligoribonucleotides carrying carbohydrates (1-6). 
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Figure 1.   HPLC profile of the product obtained after the synthesis of the 
oligoribonucleotide bearing glucose (5'- Glucose-C3-GUGCCUAUGUCUCAGCCUC-
dT-dT-3’) using DMT off conditions (see experimental section). Product eluting at 8 
min is the desired oligonucleotide. 
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Figure 2.   In vitro potency of glucose modified siRNAs against murine TNF-a in Hela 
cells using oligofectamine as transfecting agent for siRNA. The amount of murine TNF-
a produced after 24 hrs of transfection of 50nM siRNA unmodified duplex (Unm), 50 
nM of the same siRNA duplex carrying a glucose C3 molecule at the 5’-end of the 
passenger strand (1), 50 nM of the same siRNA duplex carrying two (3) and four (5) 
glucose C2 molecules at the 5’-end of the passenger strand and 50 nM of a scrambled 
RNA duplex control sequence (Scr). Error bars represent the s.d of the mean. Statistical 
analysis was by ANOVA with Bonferroni post-test, one tailed. *** P<0.001 compared 
with scrambled siRNA. 
 
 
 
Unm 1 3 5 Scr
0
100
200
300
400
500
600
***
**
***
TN
F-
a
 (p
g/
m
l)
 23
Figure 3.   In vitro potency of galactose modified siRNAs against murine TNF-a in 
Hela cells using oligofectamine as transfecting agent for siRNA. The amount of murine 
TNF-a produced after 24 hrs of transfection of 50nM siRNA unmodified duplex (Unm), 
50 nM of the same siRNA duplex carrying a galactose C2 molecule at the 5’-end of the 
passenger strand (2), 50 nM of the same siRNA duplex carrying two (4) and four (6) 
galactose C2 molecules at the 5’-end of the passenger strand and 50 nM of a scrambled 
RNA duplex control sequence (Scr). Error bars represent the s.d of the mean. Statistical 
analysis was by ANOVA with Bonferroni post-test, one tailed. *** P<0.001 compared 
with scrambled siRNA. 
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Figure 4.   In vitro potency of glucose modified siRNAs against murine TNF-a in Hela 
cells without using oligofectamine as transfecting agent for siRNA. The amount of 
murine TNF-a produced after 24 hrs of transfection of 100nM siRNA unmodified 
duplex (Unm), 100 nM of the same siRNA duplex carrying a glucose C3 molecule at 
the 5’-end of the passenger strand (1), 100nM of the same siRNA duplex carrying two 
(3) and four (5) glucose C2 molecules at the 5’-end of the passenger strand and 100 nM 
of a scrambled RNA duplex control sequence (Scr). Error bars represent the s.d of the 
mean.  
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Figure 5.   In vitro potency of galactose modified siRNAs against murine TNF-a in 
HuH-7 cells without using oligofectamine as transfecting agent for siRNA. The amount 
of murine TNF-a produced after 24 hrs of transfection of 100nM siRNA unmodified 
duplex (Unm), 100 nM of the same siRNA duplex carrying a galactose C2 molecule at 
the 5’-end of the passenger strand (2), 100nM of the same siRNA duplex carrying two 
(4) and four (6) galactose C2 molecules at the 5’-end of the passenger strand and 100 
nM of a scrambled RNA duplex control sequence (Scr). Error bars represent the s.d of 
the mean.  
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Figure 6. Competition assay between a-D-galactopyranosyl-TRICT-albumine and 
galactose-siRNAs for the asialoglycoprotein receptor. HuH-7 cells were transfected 
with pCAm TNF-a plasmid using lipofectine. One hour later 100 mM of the 
corresponding siRNA was added together with 100 times excess of the a-D-
galactopyranosyl-TRICT-albumine ligand directly to the cells without using 
transfecting agent. After 48 hours the amount of TNF-a was measured by ELISA. Error 
bars represents the s.d of the mean. 
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